Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Executive Summary
Merck will conduct a 6,000-patient study of Arcoxia focusing on patient discontinuations due to gastrointestinal adverse events
You may also be interested in...
Pfizer Celebrex Revised Labeling Adds Class Cardio Risk, Moves Safety Data
Pfizer appears to have used the relabeling of its COX-2 inhibitor Celebrex to add class cardiovascular risk language as an opportunity to renegotiate the placement of safety data
Pfizer Celebrex Revised Labeling Adds Class Cardio Risk, Moves Safety Data
Pfizer appears to have used the relabeling of its COX-2 inhibitor Celebrex to add class cardiovascular risk language as an opportunity to renegotiate the placement of safety data
FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib
Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review